文献速递白血病造血干细胞移植与细胞治疗

CD19/22 CAR T细胞治疗儿童及年轻成人B细胞急性淋巴细胞白血病:1期结果与新型双顺反子CAR的开发

CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR.
PubMed 文献 · Blood · 2022-01-01

这项1期剂量递增研究评估了新型鼠干细胞病毒(MSCV)-CD19/CD22-4-1BB双价CAR T细胞(CD19.22.BBζ)治疗儿童及年轻成人B细胞恶性肿瘤的安全性和疗效。20例B-ALL患者中完全缓解率为60%(12/20),CAR初治患者为71.4%(10/14);50%发生细胞因子释放综合征(CRS),15%为≥3级CRS,仅1例发生3级神经毒性。达到完全缓解者6个月和12个月无复发生存率分别为80.8%(95%CI:42.4%-94.9%)和57.7%(95%CI:22.1%-81.9%)。

要点

  • CD19.22.BBζ在经重度治疗的儿童及年轻成人B-ALL中完全缓解率为60%(12/20),CAR初治患者为71.4%(10/14)。
  • 50%发生CRS,15%为≥3级CRS;仅1例发生3级神经毒性。
  • 达到完全缓解者6个月和12个月无复发生存率分别为80.8%和57.7%。

核心结论

  • CD19.22.BBζ在经重度治疗的儿童及年轻成人B-ALL队列中显示出安全性和疗效,进一步优化组合抗原靶向有助于克服已发现的局限性。

研究设计与样本

  • 1期剂量递增研究,纳入20例年龄5.4至34.6岁的B-ALL患者,接受MSCV-CD19/CD22-4-1BB双价CAR T细胞(CD19.22.BBζ)治疗。
  • 主要目标为毒性和剂量探索,次要目标包括缓解率和无复发生存率(RFS),生物学相关分析包括实验室检查、CAR T细胞扩增和细胞因子谱。

主要发现

  • 全队列完全缓解率为60%(12/20),CAR初治患者为71.4%(10/14)。
  • 10例(50%)发生细胞因子释放综合征(CRS),其中3例(15%)为≥3级CRS;仅1例发生神经毒性(3级)。
  • 达到完全缓解者6个月无复发生存率为80.8%(95%CI:42.4%-94.9%),12个月为57.7%(95%CI:22.1%-81.9%)。
  • 与EF1α-CD22.BBζ相比,MSCV-CD19.22.BBζ的CAR T细胞扩增和持久性有限;实验室研究比较EF1α与MSCV启动子未显示重大差异。
  • 通过离体细胞因子分泌和人源化小鼠白血病清除实验评估,CD19.22.BBζ对CD22的靶向有限,促使开发了新型双顺反子CD19.28ζ/CD22.BBζ构建体,其抗CD22细胞因子产生增强。

局限性

  • CD19.22.BBζ的CAR T细胞扩增和持久性有限。
  • CD19.22.BBζ对CD22的靶向有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Remission durability following single-antigen targeted chimeric antigen receptor (CAR) T-cells is limited by antigen modulation, which may be overcome with combinatorial targeting. Building upon our experiences targeting CD19 and CD22 in B-cell acute lymphoblastic leukemia (B-ALL), we report on our phase 1 dose-escalation study of a novel murine stem cell virus (MSCV)-CD19/CD22-4-1BB bivalent CAR T-cell (CD19.22.BBζ) for children and young adults (CAYA) with B-cell malignancies. Primary objectives included toxicity and dose finding. Secondary objectives included response rates and relapse-free survival (RFS). Biologic correlatives included laboratory investigations, CAR T-cell expansion and cytokine profiling. Twenty patients, ages 5.4 to 34.6 years, with B-ALL received CD19.22.BBζ. The complete response (CR) rate was 60% (12 of 20) in the full cohort and 71.4% (10 of 14) in CAR-naïve patients. Ten (50%) developed cytokine release syndrome (CRS), with 3 (15%) having ≥ grade 3 CRS and only 1 experiencing neurotoxicity (grade 3). The 6- and 12-month RFS in those achieving CR was 80.8% (95% confidence interval [CI]: 42.4%-94.9%) and 57.7% (95% CI: 22.1%-81.9%), respectively. Limited CAR T-cell expansion and persistence of MSCV-CD19.22.BBζ compared with EF1α-CD22.BBζ prompted laboratory investigations comparing EF1α vs MSCV promoters, which did not reveal major differences. Limited CD22 targeting with CD19.22.BBζ, as evaluated by ex vivo cytokine secretion and leukemia eradication in humanized mice, led to development of a novel bicistronic CD19.28ζ/CD22.BBζ construct with enhanced cytokine production against CD22. With demonstrated safety and efficacy of CD19.22.BBζ in a heavily pretreated CAYA B-ALL cohort, further optimization of combinatorial antigen targeting serves to overcome identified limitations (www.clinicaltrials.gov #NCT03448393).

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Shalabi H, Qin H, Su A, et al. CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR. Blood. 2022. PMID: 35605184. doi:10.1182/blood.2022015795

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。